clofazimine has been researched along with Extensively Drug-Resistant Tuberculosis in 25 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
Extensively Drug-Resistant Tuberculosis: Tuberculosis resistant to ISONIAZID and RIFAMPIN and at least three of the six main classes of second-line drugs (AMINOGLYCOSIDES; polypeptide agents; FLUOROQUINOLONES; THIOAMIDES; CYCLOSERINE; and PARA-AMINOSALICYLIC ACID) as defined by the CDC.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We explored the potential synergistic effect of bedaquiline (BDQ) combined with moxifloxacin (MFX), gatifloxacin (GAT), clofazimine (CLO), and linezolid (LZD) for treatment of extensively drug-resistant tuberculosis (XDR-TB)." | 7.91 | No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis. ( Chu, N; Dai, G; Dong, L; Huang, H; Huo, F; Jing, W; Li, Y; Lu, J; Pang, Y; Zong, Z, 2019) |
| " The pooled proportion of adverse drug reactions requiring discontinuation of Cfz treatment was 0." | 6.50 | Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. ( Dotsenko, S; Falzon, D; Hwang, TJ; Jafarov, A; Jaramillo, E; Keshavjee, S; Lunte, K; Nunn, P; Wares, DF; Weyer, K, 2014) |
| "Clofazimine was associated with improved culture conversion in the treatment of XDR-TB/HIV." | 5.40 | Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study. ( Gopal, M; Master, I; Naidoo, K; Naidoo, R; O'Donnell, MR; Padayatchi, N; Werner, L, 2014) |
| "Large studies on bedaquiline used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) are lacking." | 3.85 | Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. ( Akkerman, O; Aleksa, A; Alffenaar, JW; Amale, R; Artsukevich, J; Belilovski, E; Borisov, SE; Bruchfeld, J; Caminero, JA; Carpena Martinez, I; Centis, R; Codecasa, L; D'Ambrosio, L; Dalcolmo, M; Davies Forsman, L; Denholm, J; Dheda, K; Douglas, P; Duarte, R; Enwerem, M; Esmail, A; Fadul, M; Filippov, A; Gaga, M; Ganatra, S; Garcia-Fuertes, JA; García-García, JM; González Montaner, P; Gualano, G; Jonsson, J; Kunst, H; Lau, JS; Lazaro Mastrapa, B; Manga, S; Manika, K; Maryandyshev, A; Migliori, GB; Mullerpattan, J; Oelofse, S; Ortelli, M; Palmero, DJ; Palmieri, F; Papalia, A; Papavasileiou, A; Payen, MC; Pontali, E; Robalo Cordeiro, C; Romero Leyet, R; Saderi, L; Sadutshang, TD; Sanukevich, T; Skrahina, A; Solodovnikova, V; Sotgiu, G; Spanevello, A; Teran Troya, JL; Tiberi, S; Topgyal, S; Toscanini, F; Tramontana, AR; Udwadia, ZF; Viggiani, P; White, V; Zumla, A, 2017) |
| " The pooled proportion of adverse drug reactions requiring discontinuation of Cfz treatment was 0." | 2.50 | Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. ( Dotsenko, S; Falzon, D; Hwang, TJ; Jafarov, A; Jaramillo, E; Keshavjee, S; Lunte, K; Nunn, P; Wares, DF; Weyer, K, 2014) |
| "Clofazimine (CFZ) is a fat-soluble riminophenazine dye used in the treatment of leprosy worldwide." | 2.49 | Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. ( Gopal, M; Metcalfe, JZ; O'Donnell, MR; Padayatchi, N, 2013) |
| " Weight-based dosing in patients <50 kg and ≥50 kg must be considered to achieve optimal treatment outcomes and reduce adverse events." | 1.56 | Dose-related treatment outcomes in South African patients prescribed clofazimine for drug-resistant tuberculosis. ( Misra, N; Naidoo, P; Padayatchi, N, 2020) |
| " Group 5 anti-tuberculosis drugs have an unclear role in the treatment of drug-resistant TB, and in children the efficacy, safety and effects of long-term use are not well described." | 1.43 | Treating children for drug-resistant tuberculosis in Tajikistan with Group 5 medications. ( Achar, J; Bobokhojaev, OI; du Cros, P; Dusmatova, Z; Quinnell, S; Seddon, JA; Swaminathan, A, 2016) |
| "Clofazimine was associated with improved culture conversion in the treatment of XDR-TB/HIV." | 1.40 | Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study. ( Gopal, M; Master, I; Naidoo, K; Naidoo, R; O'Donnell, MR; Padayatchi, N; Werner, L, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.00) | 29.6817 |
| 2010's | 18 (72.00) | 24.3611 |
| 2020's | 6 (24.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kabahita, JM | 1 |
| Kabugo, J | 1 |
| Kakooza, F | 1 |
| Adam, I | 1 |
| Guido, O | 1 |
| Byabajungu, H | 1 |
| Namutebi, J | 1 |
| Namaganda, MM | 1 |
| Lutaaya, P | 1 |
| Otim, J | 1 |
| Kakembo, FE | 1 |
| Kanyerezi, S | 1 |
| Nabisubi, P | 1 |
| Sserwadda, I | 1 |
| Kasule, GW | 1 |
| Nakato, H | 1 |
| Musisi, K | 1 |
| Oola, D | 1 |
| Joloba, ML | 1 |
| Mboowa, G | 1 |
| Singh, K | 1 |
| Sharma, S | 1 |
| Banerjee, T | 1 |
| Gupta, A | 1 |
| Anupurba, S | 1 |
| Diriba, G | 1 |
| Alemu, A | 1 |
| Yenew, B | 1 |
| Tola, HH | 1 |
| Gamtesa, DF | 1 |
| Mollalign, H | 1 |
| Eshetu, K | 1 |
| Moga, S | 1 |
| Abdella, S | 1 |
| Tollera, G | 1 |
| Kebede, A | 1 |
| Dangisso, MH | 1 |
| Patil, SB | 1 |
| Tamirat, M | 1 |
| Khazhidinov, K | 1 |
| Ardizzoni, E | 1 |
| Atger, M | 1 |
| Austin, A | 1 |
| Baudin, E | 1 |
| Bekhit, M | 1 |
| Bektasov, S | 1 |
| Berikova, E | 1 |
| Bonnet, M | 1 |
| Caboclo, R | 1 |
| Chaudhry, M | 1 |
| Chavan, V | 1 |
| Cloez, S | 1 |
| Coit, J | 1 |
| Coutisson, S | 1 |
| Dakenova, Z | 1 |
| De Jong, BC | 1 |
| Delifer, C | 1 |
| Demaisons, S | 1 |
| Do, JM | 1 |
| Dos Santos Tozzi, D | 1 |
| Ducher, V | 1 |
| Ferlazzo, G | 1 |
| Gouillou, M | 1 |
| Khan, U | 1 |
| Kunda, M | 1 |
| Lachenal, N | 1 |
| LaHood, AN | 1 |
| Lecca, L | 1 |
| Mazmanian, M | 1 |
| McIlleron, H | 1 |
| Moreau, M | 1 |
| Moschioni, M | 1 |
| Nahid, P | 1 |
| Osso, E | 1 |
| Oyewusi, L | 1 |
| Panda, S | 1 |
| Pâquet, A | 1 |
| Thuong Huu, P | 1 |
| Pichon, L | 1 |
| Rich, ML | 1 |
| Rupasinghe, P | 1 |
| Salahuddin, N | 1 |
| Sanchez Garavito, E | 1 |
| Seung, KJ | 1 |
| Velásquez, GE | 1 |
| Vallet, M | 1 |
| Varaine, F | 1 |
| Yuya-Septoh, FJ | 1 |
| Mitnick, CD | 1 |
| Guglielmetti, L | 1 |
| Saroha, D | 1 |
| Garg, D | 1 |
| Singh, AK | 1 |
| Dhamija, RK | 1 |
| Misra, N | 1 |
| Padayatchi, N | 3 |
| Naidoo, P | 1 |
| Brouqui, P | 1 |
| Quenard, F | 1 |
| Drancourt, M | 1 |
| Borisov, SE | 1 |
| Dheda, K | 1 |
| Enwerem, M | 3 |
| Romero Leyet, R | 1 |
| D'Ambrosio, L | 2 |
| Centis, R | 2 |
| Sotgiu, G | 1 |
| Tiberi, S | 2 |
| Alffenaar, JW | 1 |
| Maryandyshev, A | 1 |
| Belilovski, E | 1 |
| Ganatra, S | 1 |
| Skrahina, A | 1 |
| Akkerman, O | 1 |
| Aleksa, A | 1 |
| Amale, R | 1 |
| Artsukevich, J | 1 |
| Bruchfeld, J | 1 |
| Caminero, JA | 3 |
| Carpena Martinez, I | 1 |
| Codecasa, L | 1 |
| Dalcolmo, M | 1 |
| Denholm, J | 1 |
| Douglas, P | 1 |
| Duarte, R | 1 |
| Esmail, A | 1 |
| Fadul, M | 1 |
| Filippov, A | 1 |
| Davies Forsman, L | 1 |
| Gaga, M | 1 |
| Garcia-Fuertes, JA | 1 |
| García-García, JM | 1 |
| Gualano, G | 1 |
| Jonsson, J | 1 |
| Kunst, H | 1 |
| Lau, JS | 1 |
| Lazaro Mastrapa, B | 1 |
| Teran Troya, JL | 1 |
| Manga, S | 1 |
| Manika, K | 1 |
| González Montaner, P | 1 |
| Mullerpattan, J | 1 |
| Oelofse, S | 1 |
| Ortelli, M | 1 |
| Palmero, DJ | 1 |
| Palmieri, F | 1 |
| Papalia, A | 1 |
| Papavasileiou, A | 1 |
| Payen, MC | 1 |
| Pontali, E | 1 |
| Robalo Cordeiro, C | 1 |
| Saderi, L | 1 |
| Sadutshang, TD | 2 |
| Sanukevich, T | 1 |
| Solodovnikova, V | 1 |
| Spanevello, A | 1 |
| Topgyal, S | 1 |
| Toscanini, F | 1 |
| Tramontana, AR | 1 |
| Udwadia, ZF | 1 |
| Viggiani, P | 1 |
| White, V | 1 |
| Zumla, A | 1 |
| Migliori, GB | 3 |
| Piubello, A | 1 |
| Scardigli, A | 2 |
| Pang, Y | 3 |
| Zong, Z | 2 |
| Huo, F | 2 |
| Jing, W | 3 |
| Ma, Y | 1 |
| Dong, L | 2 |
| Li, Y | 2 |
| Zhao, L | 1 |
| Fu, Y | 1 |
| Huang, H | 3 |
| Wang, Q | 1 |
| Liu, Y | 1 |
| Wang, N | 1 |
| Yin, H | 1 |
| Zhang, Q | 1 |
| Ye, Z | 1 |
| Zhu, M | 1 |
| Li, F | 1 |
| Liu, P | 1 |
| Wu, T | 1 |
| Chen, W | 1 |
| Wu, W | 1 |
| Qin, Z | 1 |
| Qiu, C | 1 |
| Deng, Q | 1 |
| Xu, T | 1 |
| Wang, J | 2 |
| Guo, R | 1 |
| Du, Y | 1 |
| Chen, X | 1 |
| Chu, N | 2 |
| Ndjeka, N | 1 |
| Schnippel, K | 1 |
| Master, I | 2 |
| Meintjes, G | 1 |
| Maartens, G | 1 |
| Romero, R | 1 |
| Padanilam, X | 2 |
| Chotoo, S | 1 |
| Singh, N | 1 |
| Hughes, J | 1 |
| Variava, E | 1 |
| Ferreira, H | 1 |
| Te Riele, J | 1 |
| Ismail, N | 1 |
| Mohr, E | 1 |
| Bantubani, N | 1 |
| Conradie, F | 1 |
| Nkurunziza, J | 1 |
| Karstaedt, AS | 1 |
| Louw, R | 1 |
| Lee, SFK | 1 |
| Laughon, BE | 1 |
| McHugh, TD | 1 |
| Lipman, M | 1 |
| Lu, J | 1 |
| Dai, G | 1 |
| Gopal, M | 2 |
| Metcalfe, JZ | 1 |
| O'Donnell, MR | 2 |
| Hwang, TJ | 1 |
| Dotsenko, S | 1 |
| Jafarov, A | 1 |
| Weyer, K | 1 |
| Falzon, D | 1 |
| Lunte, K | 1 |
| Nunn, P | 1 |
| Jaramillo, E | 1 |
| Keshavjee, S | 1 |
| Wares, DF | 1 |
| Naidoo, R | 1 |
| Werner, L | 1 |
| Naidoo, K | 1 |
| Aggarwal, R | 1 |
| Purohit, S | 1 |
| Nemade, P | 1 |
| Panjwani, T | 1 |
| Swaminathan, A | 1 |
| du Cros, P | 1 |
| Seddon, JA | 1 |
| Quinnell, S | 1 |
| Bobokhojaev, OI | 1 |
| Dusmatova, Z | 1 |
| Achar, J | 1 |
| McNaughton, A | 1 |
| Blackmore, T | 1 |
| McNaughton, H | 1 |
| Wallis, RS | 1 |
| Tadolini, M | 1 |
| Lingtsang, RD | 1 |
| Jain, NK | 1 |
| Agnihotri, SP | 1 |
| Sharma, KK | 1 |
| Gupta, S | 1 |
| Gupta, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Controlled, Multi-center Clinical Trial of Short Course Treatment for Newly Diagnosed Rifampicin Resistant Tuberculosis[NCT04545788] | 200 participants (Anticipated) | Interventional | 2020-08-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for clofazimine and Extensively Drug-Resistant Tuberculosis
| Article | Year |
|---|---|
Epidemiology of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: A systematic review and meta-analysis.
Topics: Antitubercular Agents; Clofazimine; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Human | 2023 |
Old antibiotics for emerging multidrug-resistant/extensively drug-resistant tuberculosis (MDR/XDR-TB).
Topics: Antitubercular Agents; Clarithromycin; Clofazimine; Drug Resistance, Multiple, Bacterial; Drug Syner | 2017 |
New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease.
Topics: Amikacin; Anti-Bacterial Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculo | 2019 |
Systematic review of clofazimine for the treatment of drug-resistant tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Extensively Drug-Resistant Tuberculosis; Humans; Microb | 2013 |
Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies.
Topics: Clofazimine; Cohort Studies; Extensively Drug-Resistant Tuberculosis; Humans; Leprostatic Agents; Pr | 2014 |
2 trials available for clofazimine and Extensively Drug-Resistant Tuberculosis
| Article | Year |
|---|---|
Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial.
Topics: Antitubercular Agents; Clinical Trials, Phase III as Topic; Clofazimine; Extensively Drug-Resistant | 2023 |
Clofazimine for Treatment of Extensively Drug-Resistant Pulmonary Tuberculosis in China.
Topics: Adult; Aged; Antitubercular Agents; China; Clofazimine; Extensively Drug-Resistant Tuberculosis; Fem | 2018 |
18 other studies available for clofazimine and Extensively Drug-Resistant Tuberculosis
| Article | Year |
|---|---|
First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda.
Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculosis | 2022 |
Mutation detection and minimum inhibitory concentration determination against linezolid and clofazimine in confirmed XDR-TB clinical isolates.
Topics: Agar; Antitubercular Agents; Clofazimine; Cytosine; Drug Resistance, Multiple, Bacterial; Extensivel | 2022 |
Irreversible neuropathy in extremely-drug resistant tuberculosis: An unfortunate clinical conundrum.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Clofazimine; Cycloserine; Deprescriptions; Diaryl | 2020 |
Dose-related treatment outcomes in South African patients prescribed clofazimine for drug-resistant tuberculosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Body Weight; Clofazimine; Cohort | 2020 |
Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
Topics: Adult; Antitubercular Agents; Carbapenems; Clofazimine; Cohort Studies; Diarylquinolines; Drug Thera | 2017 |
Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases.
Topics: Aminosalicylic Acid; Antitubercular Agents; Carbapenems; Clofazimine; Communicable Disease Control; | 2017 |
Topics: Antitubercular Agents; Beijing; China; Clofazimine; Diarylquinolines; DNA Gyrase; Drug Resistance, M | 2017 |
High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Resistance, Bacte | 2018 |
Treatment outcomes of pre- and extensively drug-resistant tuberculosis in Johannesburg, South Africa.
Topics: Adolescent; Adult; Antitubercular Agents; Clofazimine; Extensively Drug-Resistant Tuberculosis; Fema | 2018 |
No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Synergism; Extensively Drug-Resistant Tub | 2019 |
Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study.
Topics: Adult; Antitubercular Agents; Clofazimine; Cohort Studies; Coinfection; Extensively Drug-Resistant T | 2014 |
XDR TB presenting as a transphyseal lytic lesion in the proximal tibia.
Topics: Antitubercular Agents; Child, Preschool; Clofazimine; Cycloserine; Extensively Drug-Resistant Tuberc | 2015 |
Classification of antituberculosis drugs: a new proposal based on the most recent evidence.
Topics: Antitubercular Agents; Carbapenems; Clavulanic Acid; Clofazimine; Diarylquinolines; Drug Therapy, Co | 2015 |
Treating children for drug-resistant tuberculosis in Tajikistan with Group 5 medications.
Topics: Adolescent; Amoxicillin-Potassium Clavulanate Combination; Antitubercular Agents; Child; Child, Pres | 2016 |
Comprehensive cost of treating one patient with MDR/pre-XDR-TB in Wellington, New Zealand.
Topics: Adult; Amikacin; Aminosalicylic Acid; Anti-Bacterial Agents; Antitubercular Agents; Bronchoscopy; Cl | 2016 |
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Human | 2016 |
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Human | 2016 |
Extensively drug resistance (XDR) tb is not always fatal.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Aza Compounds; Capreomycin; Clarithromycin; Clofa | 2009 |